Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.

Joshi S, Samajdar SS, Gupta A, Bhartia M, Lodha S, Bhattacharyya S, Seshadri K, Nagendra L, Unnikrishnan AG, Padhye D, Kopalle LN, Das AK, Lakhani O, Kesavadev J, Joshi A, Das S, Gadia S, Anthuvan T

Open source

DOI: 10.3389/fcdhc.2026.1733995
Published: 2026
Container: Frontiers in clinical diabetes and healthcare
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fcdhc.2026.1733995,
  title = {Dapagliflozin \& pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.},
  author = {Joshi S and Samajdar SS and Gupta A and Bhartia M and Lodha S and Bhattacharyya S and Seshadri K and Nagendra L and Unnikrishnan AG and Padhye D and Kopalle LN and Das AK and Lakhani O and Kesavadev J and Joshi A and Das S and Gadia S and Anthuvan T},
  year = {2026},
  journal = {Frontiers in clinical diabetes and healthcare},
  doi = {10.3389/fcdhc.2026.1733995},
  url = {https://doi.org/10.3389/fcdhc.2026.1733995}
}

RIS

TY  - JOUR
TI  - Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.
AU  - Joshi S
AU  - Samajdar SS
AU  - Gupta A
AU  - Bhartia M
AU  - Lodha S
AU  - Bhattacharyya S
AU  - Seshadri K
AU  - Nagendra L
AU  - Unnikrishnan AG
AU  - Padhye D
AU  - Kopalle LN
AU  - Das AK
AU  - Lakhani O
AU  - Kesavadev J
AU  - Joshi A
AU  - Das S
AU  - Gadia S
AU  - Anthuvan T
PY  - 2026
JO  - Frontiers in clinical diabetes and healthcare
DO  - 10.3389/fcdhc.2026.1733995
UR  - https://doi.org/10.3389/fcdhc.2026.1733995
ER  -

APA

S, J., SS, S., A, G., M, B., S, L., S, B., K, S., L, N., AG, U., D, P., LN, K., AK, D., O, L., J, K., A, J., S, D., S, G., & T, A. (2026). Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study.. Frontiers in clinical diabetes and healthcare. https://doi.org/10.3389/fcdhc.2026.1733995

Source records

pubmed · retrieved 2026-09-26T06:42:59.067Z